The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma. The study will focus on the early treatment response, treatment outcomes and the change in asthma control of benralizumab therapy in a real-world setting in China. This study will also describe the physician-reported reasons for discontinuation and switching of benralizumab therapy.
Patients must to be 12 years old (inclusive) at the time of signing the informed consent.
Patients with severe eosinophilic asthma prescribed with benralizumab at the discretion of the clinician.
Blood EOS≥150/ul in the 3 months prior to or EOS≥300/ul in the 1 year prior to the time of signing the informed consent.
Participating patients and/or their legally authorized representative must provide signed and dated written informed consent form prior to any study specific procedures.
Patients currently participating in any other clinical trial.
Known history of allergy or reaction to any component of the study treatment formulation.
Malignancy of any kind.
Patients with prior or ongoing treatment with benralizumab.